JP2013531679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531679A5 JP2013531679A5 JP2013518765A JP2013518765A JP2013531679A5 JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5 JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulation
- seq
- amino acid
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36120910P | 2010-07-02 | 2010-07-02 | |
| US61/361,209 | 2010-07-02 | ||
| PCT/US2011/042838 WO2012003470A2 (en) | 2010-07-02 | 2011-07-01 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Division JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013531679A JP2013531679A (ja) | 2013-08-08 |
| JP2013531679A5 true JP2013531679A5 (enExample) | 2014-08-14 |
Family
ID=45402685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518765A Pending JP2013531679A (ja) | 2010-07-02 | 2011-07-01 | 抗体製剤 |
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754195B2 (enExample) |
| EP (1) | EP2588141A4 (enExample) |
| JP (2) | JP2013531679A (enExample) |
| CN (1) | CN103108658B (enExample) |
| AU (2) | AU2011274363A1 (enExample) |
| BR (1) | BR112012033457A2 (enExample) |
| CA (1) | CA2803998A1 (enExample) |
| SG (1) | SG186421A1 (enExample) |
| WO (1) | WO2012003470A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| JP6157611B2 (ja) * | 2012-06-21 | 2017-07-05 | ユセベ ファルマ ソシエテ アノニム | 医薬製剤 |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| NZ719036A (en) * | 2013-09-27 | 2022-02-25 | Genentech Inc | Anti-pdl1 antibody formulations |
| JP6799904B2 (ja) * | 2014-07-31 | 2020-12-16 | キユーピー株式会社 | 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法 |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| PT3380525T (pt) * | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
| US20190046641A1 (en) | 2015-11-30 | 2019-02-14 | Medimmune, Llc | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| IL286601B2 (en) | 2015-12-16 | 2023-09-01 | Regeneron Pharma | Preparations and methods for making protein microparticles |
| CN105920600A (zh) * | 2016-04-19 | 2016-09-07 | 上海景泽生物技术有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| JP2024502825A (ja) | 2020-12-30 | 2024-01-23 | エーマックス バイオ， インコーポレイテッド | 抗体の局所的延長放出 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| ATE397659T1 (de) | 1989-02-09 | 2008-06-15 | Us Health | Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung |
| DE69231128T2 (de) | 1991-01-31 | 2001-02-15 | Cor Therapeutics, Inc. | Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden |
| IE920318A1 (en) | 1991-01-31 | 1992-07-29 | Univ California | Human platelet-derived growth factor receptors |
| US5444151A (en) | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JP3919235B2 (ja) * | 1997-06-13 | 2007-05-23 | ジェネンテク，インコーポレイテッド | 抗体製剤 |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| WO2002030463A2 (en) * | 2000-10-12 | 2002-04-18 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| WO2003068259A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| CA2508214A1 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2560046A1 (en) | 2004-03-16 | 2005-09-22 | Dnavec Research Inc. | Methods for suppressing tumor proliferation |
| AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
| SI2100618T1 (sl) * | 2005-06-17 | 2014-03-31 | Imclone Llc | Antagonisti receptorja za zdravljenje metastaznega kostnega raka |
| MX2008015852A (es) * | 2006-06-14 | 2009-02-23 | Imclone Systems Inc | Formulaciones liofilizadas de anticuerpos anti-egfr. |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| ES2827180T3 (es) * | 2006-10-06 | 2021-05-20 | Amgen Inc | Formulaciones de anticuerpos estables |
| US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
-
2011
- 2011-07-01 CN CN201180042125.5A patent/CN103108658B/zh not_active Expired - Fee Related
- 2011-07-01 CA CA2803998A patent/CA2803998A1/en not_active Abandoned
- 2011-07-01 WO PCT/US2011/042838 patent/WO2012003470A2/en not_active Ceased
- 2011-07-01 SG SG2012094074A patent/SG186421A1/en unknown
- 2011-07-01 US US13/175,522 patent/US8754195B2/en not_active Expired - Fee Related
- 2011-07-01 AU AU2011274363A patent/AU2011274363A1/en not_active Abandoned
- 2011-07-01 EP EP11801508.0A patent/EP2588141A4/en not_active Withdrawn
- 2011-07-01 BR BR112012033457A patent/BR112012033457A2/pt not_active IP Right Cessation
- 2011-07-01 JP JP2013518765A patent/JP2013531679A/ja active Pending
-
2015
- 2015-08-26 JP JP2015166305A patent/JP2016026164A/ja active Pending
-
2016
- 2016-02-29 AU AU2016201291A patent/AU2016201291A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531679A5 (enExample) | ||
| Shang et al. | Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies | |
| Mejias et al. | Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection | |
| JP2020518599A5 (enExample) | ||
| JP2013543505A5 (enExample) | ||
| JP2024016177A5 (enExample) | ||
| JP2013500947A5 (enExample) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| RU2012131099A (ru) | Препарат антитела | |
| JP2021504372A5 (enExample) | ||
| JP2018188437A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| JP2018076350A5 (enExample) | ||
| Hassett et al. | Development of a highly thermostable, adjuvanted human papillomavirus vaccine | |
| RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| CN111050791A (zh) | 用于抗tim-3抗体的给药方案及其用途 | |
| JP2020158505A5 (enExample) | ||
| JP2019509311A5 (enExample) | ||
| JP2016520075A5 (enExample) | ||
| JP2017514868A5 (enExample) | ||
| JP2013537212A5 (enExample) | ||
| JP2019501920A5 (enExample) | ||
| RU2018129077A (ru) | Стабильная фармацевтическая композиция |